Bone Biologics Corporation

NasdaqCM:BBLG Stock Report

Market Cap: US$1.9m

Bone Biologics Management

Management criteria checks 4/4

Bone Biologics' CEO is Jeff Frelick, appointed in Jun 2019, has a tenure of 4.67 years. total yearly compensation is $376.60K, comprised of 79.7% salary and 20.3% bonuses, including company stock and options. directly owns 0.4% of the company’s shares, worth $7.74K. The average tenure of the management team and the board of directors is 9.3 years and 12.1 years respectively.

Key information

Jeff Frelick

Chief executive officer


Total compensation

CEO salary percentage79.7%
CEO tenure4.7yrs
CEO ownership0.4%
Management average tenure9.3yrs
Board average tenure12.1yrs

Recent management updates

Recent updates

Companies Like Bone Biologics (NASDAQ:BBLG) Are In A Position To Invest In Growth

Jun 07
Companies Like Bone Biologics (NASDAQ:BBLG) Are In A Position To Invest In Growth

Bone Biologics prices $5.1M underwritten public offering

Oct 07

We're Not Very Worried About Bone Biologics' (NASDAQ:BBLG) Cash Burn Rate

Mar 18
We're Not Very Worried About Bone Biologics' (NASDAQ:BBLG) Cash Burn Rate

CEO Compensation Analysis

How has Jeff Frelick's remuneration changed compared to Bone Biologics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$377kUS$300k


Sep 30 2023n/an/a


Jun 30 2023n/an/a


Mar 31 2023n/an/a


Dec 31 2022US$415kUS$300k


Sep 30 2022n/an/a


Jun 30 2022n/an/a


Mar 31 2022n/an/a


Dec 31 2021US$290kUS$245k


Sep 30 2021n/an/a


Jun 30 2021n/an/a


Mar 31 2021n/an/a


Dec 31 2020US$300kUS$240k


Sep 30 2020n/an/a


Jun 30 2020n/an/a


Mar 31 2020n/an/a


Dec 31 2019US$300kUS$240k


Sep 30 2019n/an/a


Jun 30 2019n/an/a


Mar 31 2019n/an/a


Dec 31 2018US$300kUS$240k


Sep 30 2018n/an/a


Jun 30 2018n/an/a


Mar 31 2018n/an/a


Dec 31 2017US$300kUS$240k


Compensation vs Market: Jeff's total compensation ($USD376.60K) is below average for companies of similar size in the US market ($USD667.91K).

Compensation vs Earnings: Jeff's compensation has been consistent with company performance over the past year.


Jeff Frelick (57 yo)





Mr. Jeffrey Frelick, also known as Jeff, has been the President and Chief Executive Officer at Bone Biologics Corporation since June 28, 2019. He served as Chief Operating Officer at Bone Biologics, Corp....

Leadership Team

Jeffrey Frelick
CEO & President4.7yrsUS$376.60k0.40%
$ 7.7k
Deina Walsh
Chief Financial Officer9.3yrsUS$238.30k0.35%
$ 6.8k
Shun'ichi Kuroda
Co-Founder & Member of Scientific Advisory Board20.1yrsno datano data


Average Tenure

Experienced Management: BBLG's management team is seasoned and experienced (9.3 years average tenure).

Board Members

Shun'ichi Kuroda
Co-Founder & Member of Scientific Advisory Board19.1yrsno datano data
Bruce Stroever
Independent Director12.1yrsUS$76.88k0%
$ 0
Jeffrey Wang
Member of Scientific Advisory Board19.1yrsno datano data
Xinli Zhang
Member of Scientific Advisory Board19.1yrsno datano data
Robert Gagnon
Independent Directorless than a yearno data0%
$ 0
Don Hankey
Chairman of the Board9.5yrsno data1.09%
$ 21.0k
Siddhesh Angle
Independent Director2.3yrsUS$76.88k0%
$ 0


Average Tenure


Average Age

Experienced Board: BBLG's board of directors are seasoned and experienced ( 12.1 years average tenure).

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.